cntx-20260417

Table of Contents

PRELIMINARY COPY DATED APRIL 17, 2026, SUBJECT TO COMPLETION

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No. )


Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
x			Preliminary Proxy Statement
o			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o			Definitive Proxy Statement
o			Definitive Additional Materials
o			Soliciting Material under §240.14a-12


Context Therapeutics Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)


Payment of Filing Fee (Check all boxes that apply):
x			No fee required
o			Fee paid previously with preliminary materials
o			Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Table of Contents

April 28, 2026

To our stockholders:

We are pleased to invite you to attend the 2026 Annual Meeting of Stockholders of Context Therapeutics Inc. to be held on Wednesday, June 24, 2026 at 8:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/CNTX2026 and entering your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you).

Details regarding admission to the Annual Meeting and the business to be conducted at the Annual Meeting are described in the accompanying Notice of Annual Meeting of Stockholders and proxy statement.

We have elected to provide access to our proxy materials over the Internet under the U.S. Securities and Exchange Commission's "notice and access" rules. As a result, we are sending to our stockholders a notice instead of paper copies of this proxy statement and our 2025 Annual Report. The notice contains instructions on how to access those documents over the Internet. The notice also contains instructions on how stockholders can receive a paper copy of our proxy materials, including this proxy statement, our 2025 Annual Report and a form of proxy card or voting instruction form. We believe that providing our proxy materials over the Internet increases the ability of our stockholders to connect with the information they need, while reducing the environmental impact and cost of our Annual Meeting.

Your vote is important. Whether or not you plan to attend the Annual Meeting, we hope you will submit a proxy to vote as soon as possible. You may submit a proxy by telephone or through the Internet by following the instructions on the notice you received, or, if you receive a paper proxy card or voting instruction form by mail, by completing and returning the proxy card or voting instruction form mailed to you. Please carefully review the instructions on each of your voting options described in this proxy statement, as well as in the notice you receive.

Thank you for your ongoing support of and continued interest in Context Therapeutics Inc. We look forward to your participation at the Annual Meeting.


Sincerely,
/s/ MARTIN LEHR
Martin Lehr
Chief Executive Officer

Table of Contents

CONTEXT THERAPEUTICS INC.

2001 Market Street, Suite 3915, Unit #15

Philadelphia, Pennsylvania 19103

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Be Held On June 24, 2026

To the Stockholders of Context Therapeutics Inc.:

NOTICE IS HEREBY GIVEN that the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Context Therapeutics Inc., a Delaware corporation (the "Company") will be held on Wednesday, June 24, 2026 at 8:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/CNTX2026 and entering your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you). There is no physical location for the Annual Meeting. The purpose of the Annual Meeting will be the following:

1.To elect seven director nominees to our Board of Directors, each to serve until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and qualified or until his or her earlier death, resignation or removal.

2.To ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 200,000,000 to 300,000,000.

4.To approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Annual Meeting.

5.To conduct any other business properly brought before the Annual Meeting.

These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the Annual Meeting is April 27, 2026. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any adjournment or postponement thereof.

For the ten days prior to the Annual Meeting, a list of stockholders entitled to vote at the Annual Meeting will be available for examination by any stockholder of record for purposes germane to the Annual Meeting. You may make a request by calling our corporate headquarters at (267) 225-7416 during regular business hours.


By Order of the Board of Directors,

/s/ ALEX LEVIT
Alex Levit
Corporate Secretary

Philadelphia, Pennsylvania

April 28, 2026


You are cordially invited to attend the Annual Meeting via our virtual meeting platform. Whether or not you expect to attend the Annual Meeting, please vote by telephone or through the Internet prior to the Annual Meeting, or, if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you, as promptly as possible in order to ensure your representation at the Annual Meeting. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card and included in the accompanying Proxy Statement. Even if you have voted by proxy, you may still vote online while attending the Annual Meeting. Please note, however, that if your shares are held of record by a brokerage firm, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that agent in order to vote your shares that are held in such agent's name and account.

Table of Contents

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on June 24, 2026

The notice of annual meeting of stockholders, proxy statement and 2025 Annual Report are available at www.proxyvote.com.

Table of Contents


			Page
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING			1
INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS			8
INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE			13
PROPOSAL 1 —ELECTION OF DIRECTORS			17
PROPOSAL 2—RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			17
PROPOSAL 3 —APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF OUR COMMON STOCK			19
PROP OSAL 4 —APPROVAL OF THE ADJOUR N MENT PROP O SAL			22
EXECUTIVE OFFICERS			22
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT			24
EXECUTIVE COMPENSATION			26
DIRECTOR COMPENSATION			31
EQUITY COMPENSATION PLAN INFORMATION			33
DELINQUENT SECTION 16(a) REPORTS			33
TRANSACTIONS WITH RELATED PERSONS			35
HOUSEHOLDING OF PROXY MATERIALS			35
OTHER MATTERS			36
A PPENDIX A			37

Table of Contents

CONTEXT THERAPEUTICS INC.

2001 Market Street, Suite 3915, Unit #15

Philadelphia, Pennsylvania 19103

PROXY STATEMENT

FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS

To Be Held On June 24, 2026

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING

We are providing you with these proxy materials because the Board of Directors of Context Therapeutics Inc. (the "Board") is soliciting your proxy to vote at the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Context Therapeutics Inc. (the "Company"), including at any adjournments or postponements thereof, to be held on Wednesday, June 24, 2026 at 8:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/CNTX2026 and entering your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you). You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. However, you do not need to attend the Annual Meeting to have your shares voted at the Annual Meeting. Instead, you may simply follow the instructions below to submit your proxy. The proxy materials, including this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2025, are being distributed and made available on or about April 28, 2026. As used in this Proxy Statement, references to "we," "us," "our," "Context" and the "Company" refer to Context Therapeutics Inc. and our consolidated subsidiaries.

Why did I receive a Notice of Internet Availability of Proxy Materials on the Internet instead of a full set of proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the Internet rather than printing and mailing the proxy materials. We believe electronic delivery will expedite the receipt of materials and will help lower our costs and reduce the environmental impact of our annual meeting materials. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements of the Annual Meeting.

The Notice will provide instructions as to how stockholders may access and review the proxy materials, including the Notice of Annual Meeting, proxy statement, proxy card and Annual Report on Form 10-K, on the website referred to in the Notice or, alternatively, how to request that a copy of the proxy materials, including a proxy card, be sent to them by mail. The Notice will also provide voting instructions. In addition, stockholders of record may request to receive the proxy materials in printed form by mail or electronically by e-mail on an ongoing basis for future stockholder meetings. Please note that, while our proxy materials are available at the website referenced in the Notice, and our Notice of Annual Meeting, proxy statement and Annual Report on Form 10-K are available on our website, no other information contained on either website is incorporated by reference in or considered to be a part of this document.

We intend to send the Notice on or about April 28, 2026 to all stockholders of record entitled to vote at the Annual Meeting. The proxy materials, including the Notice of 2026 Annual Meeting of Stockholders, this proxy statement and accompanying proxy card or, for shares held in street name (held for your account by a broker or other nominee), voting instruction form, and the Annual Report on Form 10-K for the year ended December 31, 2025, will be made available to stockholders on the Internet on the same date.

Will I receive any other proxy materials by mail?

You will not receive any additional proxy materials via mail unless (1) you request a printed copy of the proxy materials in accordance with the instructions set forth in the Notice or (2) we elect, in our discretion, to send you a proxy card and a second Notice of Internet Availability of Proxy Materials.

Table of Contents

How do I attend the Annual Meeting?

The Annual Meeting will be held on Wednesday, June 24, 2026 at 8:00 a.m. Eastern Time. The Annual Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. There will be no physical meeting location. To participate, you can access the Annual Meeting by visiting www.virtualshareholdermeeting.com/CNTX2026 and entering your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you). Prior to the Annual Meeting, you should ensure that you have a strong WiFi connection. We also recommend that you log in a few minutes before the Annual Meeting on June 24, 2026 to ensure you are logged in when the meeting starts and to ensure that you can hear streaming audio prior to the start of the meeting. Online check-in will begin at 7:45 a.m. Eastern Time on June 24, 2026.

We have decided to hold a virtual meeting because it improves stockholder access, encourages greater global participation, lowers costs compared to an in-person event, and aligns with our broader sustainability goals. Stockholders attending the virtual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting. Information on how to vote online while attending the Annual Meeting is discussed below.

Can I ask questions at the Annual Meeting?

Only stockholders of record as of the record date for the Annual Meeting and their proxy holders may submit questions or comments at the Annual Meeting. If you would like to submit a question, you may do so by joining the virtual Annual Meeting at www.virtualshareholdermeeting.com/CNTX2026 using your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you), and typing your question in the box in the Annual Meeting portal.

To help ensure that we have a productive and efficient meeting, and in fairness to all stockholders in attendance, you will also find posted our rules of conduct for the Annual Meeting when you log in prior to its start. In accordance with the rules of conduct, we ask that you limit your remarks to one brief question or comment that is relevant to the Annual Meeting or our business and that remarks are respectful of your fellow stockholders and meeting participants. Questions may be grouped by topic by our management with a representative question read aloud and answered. In addition, questions may be ruled as out of order if they are, among other things, irrelevant to our business, related to pending or threatened litigation, disorderly, repetitious of statements already made, or in furtherance of the speaker’s own personal, political or business interests. Questions will be addressed in the Q&A portion of the Annual Meeting.

What if I need technical assistance accessing or participating in the virtual Annual Meeting?

If you encounter any difficulties accessing the virtual Annual Meeting during the check-in or meeting time, please call toll free: 1-844-986-0822, or if calling internationally, please call: 1-303-562-9302.

Who can vote at the Annual Meeting?

Only stockholders of record at the close of business on April 27, 2026 or their duly appointed proxies will be entitled to vote online while attending the Annual Meeting. On this record date, there were 91,879,177 shares of common stock outstanding and entitled to vote.

Stockholder of Record: Shares Registered in Your Name

If on April 27, 2026, your shares were registered directly in your name with our transfer agent, Equiniti Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you may vote online while attending the Annual Meeting or submit a proxy to vote your shares. Whether or not you plan to attend the Annual Meeting, we urge you to submit a proxy to vote your shares electronically through the Internet prior to the meeting, over the telephone, or by completing and returning a printed proxy card that you may request or that we may elect to deliver at a later time to ensure your vote is counted.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on April 27, 2026, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in "street name" and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting and may vote online while attending.

Table of Contents

What am I voting on?

There are four matters scheduled for a vote:

•Election of seven director nominees to our Board of Directors, each to serve until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and qualified or until his or her earlier death, resignation or removal (Proposal 1).

•Ratification of the selection by the Audit Committee of the Board of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 (Proposal 2).

•Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 200,000,000 to 300,000,000 (Proposal 3).

•Approval of one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Annual Meeting (Proposal 4).

What if another matter is properly brought before the Annual Meeting?

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons acting as proxies to vote on those matters in accordance with their best judgment.

How do I vote?

With respect to Proposal 1, you may vote “FOR ALL” nominees, “WITHHOLD ALL” nominees or “FOR ALL EXCEPT” those nominees noted by you on the appropriate portion of your proxy or voting instructions. With respect to Proposals 2, 3 and 4, you may either vote “FOR” or “AGAINST” or abstain from voting.

The procedures for voting are fairly simple:

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you may vote online while attending the Annual Meeting, submit a proxy over the telephone, submit a proxy through the Internet prior to the Annual Meeting, or submit a proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the Annual Meeting, we urge you to submit a proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote online during the Annual Meeting even if you have already submitted a proxy.

•To vote online during the Annual Meeting, join the virtual Annual Meeting at www.virtualshareholdermeeting.com/CNTX2026 using your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you) and follow the instructions in the Annual Meeting portal.

•To submit your proxy by using a printed proxy card that may be delivered to you, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.

•To submit your proxy over the telephone, dial toll-free (800) 690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice. Your telephone proxy must be received by 11:59 p.m., Eastern Time on June 23, 2026 to be counted, and your shares will be voted as you direct.

•To submit your proxy through the Internet without attending the Annual Meeting, go to www.proxyvote.com to complete an electronic proxy card. Have your 16-digit control number (included on the Notice of Internet Availability of Proxy Materials sent to you) and follow the instructions in the Annual Meeting portal. Your Internet proxy must be received by 11:59 p.m., Eastern Time on June 23, 2026 to be counted, and your shares will be voted as you direct.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a Notice containing voting instructions from that organization rather than from us. Simply follow the voting instructions in the Notice to ensure that your vote is counted. You are also invited to attend the Annual Meeting and may vote online while attending.

Table of Contents


We provide Internet proxy voting to allow you to submit a proxy to vote your shares online via proxy prior to the Annual Meeting, and Internet voting to allow you to vote your shares during the Annual Meeting, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.

Can I vote my shares by filling out and returning the Notice?

No. The Notice identifies the items to be voted on at the Annual Meeting, but you cannot vote by marking the Notice and returning it. The Notice provides instructions on how to vote or submit a proxy.

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you owned as of April 27, 2026.

What happens if I do not vote?

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record and do not submit a proxy by telephone, through the Internet prior to the Annual Meeting, by completing the printed proxy card that may be delivered to you or vote online while attending the Annual Meeting, your shares will not be voted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner and do not instruct your broker, bank or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the particular proposal is considered to be a "routine" matter under applicable rules. Brokers and nominees can use their discretion to vote "uninstructed" shares with respect to matters that are considered to be "routine" under applicable rules but not with respect to "non-routine" matters. Under applicable rules and interpretations, "non-routine" matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported. Proposals 2, 3 and 4 are considered to be “routine” matters, so your broker or nominee may vote your shares in its discretion on these proposals even in the absence of your instruction.

What if I return a proxy card or otherwise vote but do not make specific choices?

If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, “FOR ALL” director nominees listed under Proposal 1, "FOR" the ratification of the selection of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, “FOR” approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our outstanding common stock from 200,000,000 to 300,000,000, and “FOR” the approval of one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Annual Meeting. If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

What does it mean if I receive more than one Notice?

If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the Notices to ensure that all of your shares are voted.

Table of Contents

Can I change my vote after submitting my proxy?

Stockholder of Record: Shares Registered in Your Name

Yes. You can revoke your proxy at any time before the vote during the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

•You may submit another properly completed proxy card with a later date (which automatically revokes the earlier proxy).

•You may grant a subsequent proxy by telephone or through the Internet prior to the Annual Meeting.

•You may send a timely written notice that you are revoking your earlier-dated proxy to our Corporate Secretary c/o Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103.

•You may attend the Annual Meeting and vote online during the meeting. Simply attending the Annual Meeting via the virtual platform will not, by itself, revoke your proxy. Even if you plan to attend the Annual Meeting, we recommend that you also submit your proxy by telephone or through the Internet so that your vote will be counted if you later decide not to attend the Annual Meeting.

Your most current proxy card or telephone or Internet proxy is the one that will be counted. Properly submitted proxies that are received in time and not subsequently revoked will be voted as instructed.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker, bank or other agent to change your voting instructions.

When are stockholder proposals and director nominations due for next year's annual meeting?

To be considered for inclusion in next year's proxy materials, you must submit your proposal, in writing, by December 29, 2026, to our Corporate Secretary c/o Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103, and you must comply with all applicable requirements of Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Pursuant to our bylaws, if you wish to bring a proposal before the stockholders or nominate a director at the 2027 Annual Meeting of Stockholders, to be timely, you must notify our Corporate Secretary between 8:00 a.m., local time, on February 24, 2027, the 120th day prior to the first anniversary of the Annual Meeting and not later than 5:00 p.m. on March 26, 2027, the 90th day prior to the first anniversary of the Annual Meeting. If the date of the 2027 Annual Meeting of Stockholders occurs more than 25 days before or after the first anniversary of the 2026 Annual Meeting of Stockholders, then to be timely, such notice must be received by our Corporate Secretary no earlier than 8:00 a.m., local time, on the 120th day prior to the 2027 Annual Meeting of Stockholders and no later than 5:00 p.m., local time, on the 10th day following the day on which public announcement of the date of the 2027 Annual Meeting of the Stockholders was first made by the Company. You are also advised to review our bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

In addition to satisfying the foregoing requirements under our bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 26, 2027.

How are votes counted and what are the effects of abstentions on the votes?

Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count, for Proposal 1 "FOR" and “WITHHOLD” votes and broker non-votes for each nominee; and for Proposals 2, 3, and 4, “FOR” and “AGAINST” votes and abstentions. Withholding a vote from a director nominee will not be voted with respect to the director nominee indicated and will have no impact on the election of directors, although it will be counted for purposes of establishing a quorum. Abstentions will have the same effect as votes cast “AGAINST” Proposals 2 and 4. Abstentions will not be counted towards the vote total for Proposals 1 and 3, and will have no effect on the voting of those proposals.

What are "broker non-votes"?

As discussed above, when a beneficial owner of shares held in "street name" does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed to be "non-routine," the broker or nominee cannot vote the shares. These unvoted shares are counted as "broker non-votes." As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting

Table of Contents

instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.

How many votes are needed to approve each proposal?

The following table summarizes the minimum vote needed to approve the proposal and the effect of abstentions and broker non-votes:

Proposal
Number

Proposal Description

Vote Required for Approval

Effect of Withholding of Votes or

Abstentions

Effect of
Broker
Non-Votes

Election of seven director nominees to our Board of Directors, each to serve until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and qualified or until his or her earlier death, resignation or removal

The seven director nominees receiving the highest number of “FOR” votes will be elected to our Board of Directors.

None

Ratification of the selection of CohnReznick LLP as our independent registered public accounting firm

To approve Proposal 2, stockholders holding a majority of the voting power of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote thereon must vote "FOR" the proposal.

Abstentions have same effect as votes cast “AGAINST”

Not applicable(1)

Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 200,000,000 to 300,000,000

To approve Proposal 3, pursuant to Section 242(d) of the DGCL, a majority of the votes cast for or against the Charter Amendment by the holders of our outstanding shares present in person or represented by proxy at the Annual Meeting and entitled to vote thereon must vote "FOR" the proposal.

None

Not applicable(1)

Approval of one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Annual Meeting

To approve Proposal 4, stockholders holding a majority of the voting power of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote thereon must vote "FOR" the proposal.

Abstentions have same effect as votes cast “AGAINST”

Not applicable(1)

(1)This proposal is considered to be a "routine" matter under New York Stock Exchange (“NYSE”) rules. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority under NYSE rules to vote your shares on this proposal.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid meeting. On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court of Chancery of the State of Delaware (the “Court”) regarding the stockholder class action complaint (the “Action”) filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against us and our directors. On March 11, 2026, the Court approved the Stipulated Judgment, which ordered us to hold a meeting of stockholders on June 24, 2026 for the election of directors pursuant to Section 211(c) of the General Corporation Law of the State of Delaware (the “DGCL”). Section 211(c) of the DGCL provides that the shares of stock represented at the Annual Meeting, either in person or by proxy, and entitled to vote thereat, shall constitute a quorum for the purpose of such meeting, notwithstanding any provision of our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws to the contrary.

However, pursuant to Nasdaq Listing Rule 5620(c), we are not permitted to utilize a quorum that is less than 33 1/3% of our outstanding shares of common stock for any stockholder meeting. As a result, although we intend to initially convene and hold the Annual Meeting on June 24, 2026, in order to remain compliant with the Nasdaq Listing Rules, in the event that holders of 33 1/3% of our outstanding shares of common stock are not initially present at the Annual Meeting, we reserve the right to adjourn the Annual Meeting one or more times as necessary until stockholders holding at least 33 1/3%

Table of Contents

of our outstanding shares of common stock as of the record date are present at the Annual Meeting by remote communication or represented by proxy. On the record date, there were 91,879,177 shares outstanding and entitled to vote.

For purposes of determining whether a quorum exists, we count as present any shares that are voted over the Internet, by telephone, by completing and submitting a proxy or that are represented by remote communication at the meeting. Further, for purposes of establishing a quorum, we will count as present shares that a stockholder holds even if the stockholder votes to abstain or only votes on one of the proposals.

Will a list of stockholders entitled to vote at the Annual Meeting be available?

How can I find out the results of the voting at the Annual Meeting?

Final voting results will be published in a Current Report on Form 8-K that we expect to file within four business days after the Annual Meeting.

Table of Contents

INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS

The Board has three committees: an Audit Committee; a Compensation Committee; and a Nominating and Corporate Governance Committee. The following table provides membership information for each of the Board committees as of April 13, 2026:

Name

Audit

Compensation

Nominating and
Corporate
Governance

Martin Lehr

Andy Pasternak

Jennifer Evans Stacey, Esq.

(1)

Philip Kantoff, MD

Karen Smith, MD

(1)

Luke Walker, MD

Linda West

(1)

____________________________

(1)Chairperson.

Below is a description of each committee of the Board.

Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq Stock Market (“Nasdaq”) rules and regulations regarding "independence" and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.

Audit Committee

The Audit Committee of the Board was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee our corporate accounting and financial reporting processes and audits of our financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee, among other things, evaluates the performance of and assesses the qualifications of our independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent registered public accounting firm as required by law; reviews and approves or disapproves transactions between the Company and any related persons; reviews and discusses with management and our independent registered public accounting firm, as appropriate, regarding the adequacy and effectiveness of internal control over financial reporting; establishes and oversees procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and reviews and discusses our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of the Company's disclosures under "Management's Discussion and Analysis of Financial Condition and Results of Operations" in its filings with the SEC.

The Audit Committee is composed of three directors: Ms. West; Mr. Pasternak; and Ms. Stacey. The Audit Committee met seven times during fiscal year 2025. On January 13, 2025, Mr. Pasternak replaced Mr. Berman on the Audit Committee immediately following the effectiveness of Mr. Berman’s resignation from the Board. The Board has adopted a written Audit Committee charter that is available to stockholders on our website at https://ir.contexttherapeutics.com on the “Governance” page.

The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all of the current members of the Audit Committee are independent (as independence is currently defined under Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing rules and under Rule 10A-3 under the Exchange Act). The Board has also determined that Ms. West qualifies as an "audit committee financial expert," as defined in applicable SEC rules. The Board made a qualitative assessment of Ms. West's level of knowledge and experience based on a number of factors, including her formal education and experience holding multiple finance leadership roles.

Table of Contents

Report of the Audit Committee of the Board of Directors

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2025 with our management. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board ("PCAOB"). The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants' communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm's independence. Based on the foregoing, the Audit Committee of the Board of Directors has recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Linda West, Chairperson

Andy Pasternak

Jennifer Evans Stacey, Esq.

The material in this report is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Compensation Committee

The Compensation Committee is composed of three directors: Mr. Pasternak, Dr. Smith, and Ms. West. On January 13, 2025, Mr. Pasternak replaced Mr. Berman on the Compensation Committee and Dr. Smith became the chair of the Compensation Committee, each immediately following the effectiveness of Mr. Berman’s resignation from the Board. In connection with her appointment as interim Chief Medical Officer, Dr. Smith did not serve on the Compensation Committee from May 1, 2025 through May 30, 2025. All members of our Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing rules). The Compensation Committee met five times during fiscal year 2025. The Board has adopted a written Compensation Committee charter that is available to stockholders on our website at https://ir.contexttherapeutics.com on the “Governance” page.

The Compensation Committee acts on behalf of the Board to:

•review our executive compensation programs to assess whether the programs are designed to enable it to recruit, retain and motivate talented and diverse executives, and are appropriately competitive, support organization objectives and stockholder interests, and create a pay for performance linkage, while also structuring compensation programs to, where determined appropriate, preserve tax deductibility;

•oversee all our material employee benefit plans and programs, including the authority to adopt, amend and terminate such plans and programs, including approving changes in the number of shares reserved for issuance thereunder, subject to any necessary or advisable approval by our Board or stockholders;

•in connection with executive compensation programs, (i) review and approve new executive compensation programs, (ii) review on a periodic basis the operations of our executive compensation programs to determine whether they are properly coordinated and achieving their intended purposes, and (iii) establish and periodically review policies for the administration of executive compensation programs;

•review and discuss annually our compensation policies and practices with management to promote the success of our business and to determine whether the policies and practices encourage excessive risk-taking, review the relationship between risk management policies and compensation and evaluate compensation policies and practices that could mitigate any such risk;

•review, approve and administer annual and long-term incentive compensation plans for executive officers and other senior executives, including by (i) establishing performance objectives and certifying performance achievement, (ii) evaluating the competitiveness of such plans, (iii) reviewing and approving all equity incentive plans and grant awards under such plans, and (iv) adopting, amending and terminating any such plans;

•administer our equity incentive plans;

•review and approve, as well as approve amendments to or terminations of, any compensatory contracts or similar transactions or arrangements with such other employees as the Compensation Committee determines, including employment agreements, severance arrangements, transition or consulting agreements, retirement agreements and change-in-control agreements or provisions;

Table of Contents

•consider for adoption and oversee any stock ownership guidelines, share retention policies or clawback policies applicable to our executive officers; and

•undertake any other tasks enumerated in the charter of the Compensation Committee.

Compensation Committee Processes and Procedures

The Compensation Committee meets as often as it deems necessary, but at least once per year. From time to time, various members of management and other employees as well as outside advisers or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. However, neither the Chief Executive Officer, nor any other executive officer, may be present during portions of any meetings during which his or her respective performance or compensation are being deliberated or determined. In addition, under its charter, the Compensation Committee has the authority to obtain, at our expense, advice and assistance from compensation consultants and internal and external legal, accounting or other advisers and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant's reasonable fees and other retention terms. Under its charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after assessing the independence of such person in accordance with SEC and Nasdaq requirements that bear upon the adviser's independence; however, there is no requirement that any adviser be independent.

During 2025, after taking into consideration the factors prescribed by the SEC and Nasdaq, the Compensation Committee engaged Cannae HR Solutions ("Cannae"), a compensation consulting firm, as a compensation consultant. The Compensation Committee has assessed Cannae’s independence and determined that Cannae had no conflicts of interest in connection with its provision of services to the Compensation Committee. Specifically, the Compensation Committee engaged Cannae to provide market data, peer group analysis and conduct an executive and board compensation assessment to help determine appropriate cash and equity compensation for our executive officers, other senior management, and our Board against compensation for similarly situated executives and directors at the companies Cannae identified, in coordination with our Compensation Committee, to be comparable to the Company, and in determining appropriate employment agreement terms for our executive officers. At the end of 2025, the Compensation Committee engaged Alpine Rewards, LLC to replace Cannae as the Company’s compensation consulting firm for 2026.

The Compensation Committee makes most of the significant adjustments to annual compensation, determines bonus and equity awards and establishes new performance objectives at one or more meetings held during the last quarter of each year and the first quarter of the following year. The Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee's process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which recommends, for approval by the independent members of the Board, any adjustments to the Chief Executive Officer’s compensation as well as equity awards to be granted. For all executives officers and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive officer and director stock ownership information, stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and recommendations of the Compensation Committee's compensation consultant, including analyses of executive officer and director compensation paid at other companies identified by such consultant to be comparable to us.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee of the Board is responsible for, among other things, developing, and recommending to the Board for its approval, criteria and qualifications for service as a director of the Company, identifying, evaluating and recommending to the Board candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing the structure and composition of each committee of the Board and continually reviewing important issues and developments in corporate governance.

Table of Contents

The Nominating and Corporate Governance Committee is composed of three directors: Ms. Stacey, Dr. Kantoff, and Dr. Walker. Each member of the Nominating and Corporate Governance Committee is independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing rules). The Nominating and Corporate Governance Committee met five times during fiscal year 2025. The Board has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders on our website at https://ir.contexttherapeutics.com on the “Governance” page.

The Nominating and Corporate Governance Committee has not established specific minimum qualifications for Board members but believes that the assessment of director qualifications may include numerous factors, such as character, professional ethics and integrity, judgment, business acumen, proven achievement and competence in one’s field, the ability to exercise sound business judgment, tenure on the Board and skills that are complementary to the Board, an understanding of the Company’s business, an understanding of the responsibilities that are required of a member of the Board, other time commitments, diversity with respect to backgrounds and experiences in various areas, as well as other individual qualities and attributes that contribute to the total mix of viewpoints and experiences represented on the Board. Unless the Board determines that the carrying out of a director’s responsibilities to the Company will not be adversely affected by the director’s other directorships: an executive officer-director will not serve on the board of more than two public companies; and directors who are not executive officers will not serve on more than four public company boards in addition to the Board of the Company.

The Nominating and Corporate Governance Committee and the Board evaluate each director in the context of the membership of the Board as a group, with the objective of maintaining a Board that can best perpetuate the success of the business and represent stockholder interests. In determining whether to recommend an incumbent director for re-election, the Nominating and Corporate Governance Committee considers the director’s past attendance at meetings, participation in and contributions to the activities of the Board and the Company and other qualifications and characteristics set forth above and in the Nominating and Corporate Governance Committee’s charter. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee may also engage, if it deems necessary or appropriate, independent counsel, search firms or other advisors.

The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders so long as such recommendations and nominations comply with our charter and bylaws, all applicable Company policies and all applicable laws, rules and regulations, and in the same manner as candidates recommended to the Nominating and Corporate Governance Committee from other sources. Stockholders may recommend director nominees for consideration by the Nominating and Corporate Governance Committee by writing to the Secretary of the Company at Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103 in accordance with the procedures set forth in the Company’s bylaws. Such recommendations must also include: the full name of the proposed nominee; the proposed nominee’s home and business contact information; detailed biographical information; relevant qualifications; a signed letter from the candidate confirming the candidate’s willingness to serve; information regarding any relationships between the candidate and the Company; evidence of the recommending stockholder’s ownership of Company stock; and a statement from the recommending stockholder in support of the candidate.

Stockholder Communications with the Board of Directors

Stockholder communications will be reviewed by our Secretary, who will determine whether the communication should be presented to the Board. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). All potential violations reported in accordance with our Code of Business Conduct and Ethics that relate to questionable accounting or auditing matters involving the Company will be promptly sent to our Chairperson of the Audit Committee and to our Chief Legal Officer, who will promptly notify the Audit Committee of all complaints that pertain to an accounting or audit matter and will determine the planned course of action. Communications regarding matters other than accounting or audit will be investigated by our Chief Legal Officer or another appropriate person designated by our Chief Legal Officer.

Corporate Governance Guidelines

We have adopted Corporate Governance Guidelines to assure that the Board will have the necessary authority and practices in place to review and evaluate our business operations as needed and to make decisions that are independent of our management. The guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to, among other things, board composition and selection including diversity, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning, and board committees and

Table of Contents

compensation. The Corporate Governance Guidelines are available on our website at https://ir.contexttherapeutics.com on the "Governance" page.

Insider Trading Policy; Prohibition on Hedging, Pledging, and Short Sales

We have adopted an insider trading policy governing the purchase, sale, and other disposition of our securities by directors, officers, employees and certain other covered persons, a copy of which is filed as an exhibit to our Annual Report on Form 10-K. The policy is designed to promote compliance with insider trading laws, rules, and regulations, as well as applicable listing standards. In addition, with regard to the Company’s trading in its own securities, it is the Company's policy to comply with the federal securities laws.

Under our insider trading policy, officers, directors and employees may not engage in short sales of our securities. Such individuals are also prohibited from engaging in hedging transactions (including prepaid variable forwards, equity swaps, collars and exchange funds), transactions in put options, call options, or other derivative securities and pledging our securities. Additionally, all officers, directors, and employees are also prohibited from holding our securities in a margin account unless first obtaining pre-clearance as set forth in our insider trading policy. The prohibition on hedging does not preclude general portfolio diversification or investing in broad-based index funds.

Code of Business Conduct

We have adopted a Code of Business Conduct and Ethics (the "Code of Conduct"), applicable to all of our employees, executives, directors and independent contractors. The Code of Conduct is available on our website at https://ir.contexttherapeutics.com on the "Governance" page. The Audit Committee is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. If we make any substantive amendments to the Code of Conduct or we grant any waiver from a provision of the Code of Conduct to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website.

Table of Contents

INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

The Board of Directors presently consists of seven members, all of whom have been nominated for re-election at the Annual Meeting. As previously disclosed, on February 24, 2026, the Stipulated Judgment was filed with the Court regarding the Action filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against us and our directors. On March 9, 2026, the Stipulated Judgment was filed with the Court of Chancery. On March 11, 2026, the Court approved the Stipulated Judgment, pursuant to which (i) Article V, Section 2 of our Amended and Restated Certificate of Incorporation, which provided that our directors shall serve for a term of three years, and (ii) Article VI, Section 1 of our Amended and Restated Certificate of Incorporation, which provided that our directors may be removed from office only for cause, were determined to be invalid and unenforceable, and we were obligated to file a Certificate of Correction with the Delaware Secretary of State within 10 business days of the Court’s entry of the order approving the Stipulated Judgment reflecting that such provisions were invalid and unenforceable and are no longer part of our Amended and Restated Certificate of Incorporation.

On March 11, 2026, we filed a Certificate of Correction with the Delaware Secretary of State reflecting such provisions as invalid, unenforceable and no longer part of our Amended and Restated Certificate of Incorporation (the “Certificate of Correction”). Accordingly, the term of office of the current members of our Board of Directors will expire at the Annual Meeting, with each serving until his or her successor is elected and qualified or until his or her earlier death, resignation or removal, and directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.

Set forth below is biographical information as of April 13, 2026 for each person nominated for election as a director at the Annual Meeting, including the specific and particular experience, qualifications, attributes or skills that led the Nominating and Corporate Governance Committee to believe that each director nominee should serve on our Board. There are no family relationships among our executive officers or directors.

Name

Age

Position(s) Held with Context

Director Since

Martin Lehr

Director, President and Chief Executive Officer

2015

Andy Pasternak

Chairman of the Board

January 2025

Philip Kantoff, MD

Director

December 2018

Karen Smith, MD, PhD, MBA, LLM

Director

September 2024

Jennifer Evans Stacey, Esq.

Director

March 2021

Luke Walker, MD

Director

September 2024

Linda West

Director

March 2021

Martin Lehr – Chief Executive Officer and Director

Mr. Lehr is the Co-founder and Chief Executive Officer of Context Therapeutics and has served as a member of our board of directors since its founding in 2015. In addition, Mr. Lehr serves on the boards of Praesidia Biotherapeutics, a private biotech company, and CureDuchenne Ventures, an impact fund that funds research and treatments for Duchenne Muscular Dystrophy. Previously, Mr. Lehr was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. Prior to Osage University Partners, Mr. Lehr conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. Mr. Lehr is a director of BioBreak, a biotech executive peer networking group with over 2,500 active members across the United States, and an advisory board member of Life Science Cares and Life Science Leader magazine. Mr. Lehr holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania. The Company has determined that Mr. Lehr’s business experience and management background make him a qualified member of our management group and board of directors.

Andy Pasternak – Chairman of the Board, Director

Mr. Pasternak has served as a member of our board of directors since January 2025 and as Chairman of the board of directors since January 2025. Mr. Pasternak is the Chief Strategy Officer at Kardigan Bio, a private biotechnology company developing therapeutics for cardiovascular diseases. Prior to joining Kardigan, Mr. Pasternak served as an advisory partner at Bain & Company, Inc. (“Bain”), a global consulting firm. Prior to Bain, Mr. Pasternak served as

Table of Contents

Executive Vice President, Chief Strategy Officer at Horizon Therapeutics plc (“Horizon”), a biotechnology company focused on serious, rare autoimmune and inflammatory diseases. Prior to joining Horizon in 2019, Mr. Pasternak was a senior partner at Bain, where he served as Head of the Healthcare Practice in the Americas. Earlier in his career, Mr. Pasternak was an analyst in the Investment Banking division of Chemical Securities, Inc. (now part of J.P. Morgan). Previously, Mr. Pasternak served on the Board of Directors of Endo, Inc., a specialty pharmaceutical company, from 2024 to 2025. Mr. Pasternak is an Adjunct Lecturer in the Healthcare Program at the Kellogg School of Management (“HCAK”), where he teaches a course about the biopharmaceutical industry, and serves on the advisory board of the HCAK program. Mr. Pasternak received his B.A. in economics from Northwestern University and an MBA from the University of Chicago. The Company has determined that Mr. Pasternak’s background and success in the life sciences industry make him a qualified member of our board of directors.

Philip Kantoff, MD – Director

Dr. Kantoff has served as a member of our board of directors since December 2018. Dr. Kantoff is the Co-Founder, Chief Executive Officer and a member of the board of directors of Convergent Therapeutics, a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. Previously, Dr. Kantoff served as the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, which is the leading development and testing center for novel cancer therapies, as well as a member of the Board of Directors of ESSA Pharma Inc. from September 2022 until March 2025. He also served as Director of The Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is the Jerome and Nancy Kohlberg Professor Emeritus at Harvard Medical School. He is a member of numerous professional societies and editorial boards. Dr. Kantoff has published more than 500 research articles on a variety of topics and has been cited over 107,000 times, written nearly 100 reviews and monographs on cancer and has edited numerous books, including Prostate Cancer: A Family Consultation, A Multi-Disciplinary Guide published by Blackwell, and Prostate Cancer: Principles and Practice, a definitive text on prostate cancer. Dr. Kantoff received his M.D. from Brown University. The Company has determined that Dr. Kantoff’s medical and business background make him a qualified member of our board of directors.

Karen Smith, MD, PhD, MBA, LLM – Director

Dr. Smith has served as a member of our board of directors since September 2024, as our interim Chief Medical Officer in May 2026 and as a consultant to support the transition to our next Chief Medical Officer in June and July of 2026. Since November 2018, Dr. Smith has been providing consulting services internationally. Dr. Smith most recently served as Chief Medical Officer for Qunice Therapeutics, Inc./Novosteo, Inc., a private biopharmaceutical company from January 2022 to September 2023, having previously served as Chief Medical Officer for Emergent BioSolutions, Inc. from April 2020 to December 2021. From May 2019 to January 2020, Dr. Smith served as President and Chief Executive Officer of Medeor Therapeutics, Inc., a biotechnology company. From June 2018 to May 2019, Dr. Smith served as Chief Executive Officer of Eliminate Cancer, Inc. From April 2015 to May 2018, she served as the Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, where she built the research and development function into a pipeline of neuroscience and oncology products across all stages of discovery and development. From 2011 to 2015, she was Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc., a multi-specialty health care company. Earlier in her career, she held senior leadership roles at AstraZeneca plc and Bristol Myers Squibb Company. Dr. Smith holds several degrees, including an M.D. from the University of Warwick, a Ph.D. in oncology from the University of Western Australia, an M.B.A. from the University of New England and an L.L.M. (Masters in Law) from the University of Salford. Dr. Smith serves on the boards of directors of public biotechnology companies Sangamo Therapeutics, Inc. and Skye Bioscience, Inc. Dr. Smith previously served on the board of directors of Aurinia Pharmaceuticals, Inc., a public biotechnology company, from August 2023 to May 2025, Talaris Therapeutics, Inc., a public biotechnology company, from June 2022 to October 2023, Antares Pharma, Inc., a public pharmaceutical company, from March 2019 to May 2022, and Acceleron Pharma, Inc., a public biopharmaceutical company, from November 2017 to December 2021. The Company has determined that Dr. Smith’s medical and business background make her a qualified member of our board of directors.

Jennifer Evans Stacey, Esq. – Director

Ms. Stacey has served as a member of our board of directors since March 2021. Ms. Stacey currently is the Chief Legal & Compliance Officer and Secretary of Neogen Corporation, a publicly traded, global leader in food safety solutions. Ms. Stacey previously served as the Chief Legal & Compliance Officer and Secretary of Galera Therapeutics Inc., a publicly traded clinical-stage biopharmaceutical company from October 2021 until August 2024, continuing in a consulting role until January 2025. Ms. Stacey has more than 25 years of global senior executive experience managing public, private and non-profit companies, ranging in size from 10 to 5,500 employees and primarily within the life sciences industry. Prior to Galera, Ms. Stacey served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, a biomedical research institute, and before that as Senior Vice President, General Counsel, Human Resources and Secretary at Antares Pharma, Inc., which was acquired by Halozyme Therapeutics, Inc. in 2022. Previously, Ms. Stacey

Table of Contents

served as Executive Vice President, General Counsel, Human Resources, and Secretary at Auxilium Pharmaceuticals, Inc., and as Senior Vice President, Corporate Communications, General Counsel and Secretary at Aventis Behring, LLC. She began her career in life sciences at Rhone-Poulenc Rorer, including two years in their Paris office and prior to that began her legal career at King & Spalding in Washington, D.C. Ms. Stacey graduated magna cum laude with an A.B. from Princeton University and earned her J.D. from the University of Pennsylvania Law School. The Company has determined that Ms. Stacey’s business and legal background make her a qualified member of our board of directors.

Luke Walker, MD – Director

Dr. Walker has served as a member of our board of directors since September 2024. Dr. Walker currently is the Chief Medical Officer of Umoja Biopharma, Inc., a clinical-stage biotech company. From October 2022 to August 2024, Dr. Walker was the Chief Medical Officer of Harpoon Therapeutics, which was acquired by Merck in March 2024. From March 2018 to October 2022, Dr. Walker was Vice President of Clinical Development at Seagen, which was acquired by Pfizer in 2023. Earlier, Dr. Walker was Senior Vice President of Clinical Development at Cascadian Therapeutics, which was acquired by Seagen in 2018. Dr. Walker began his career as a practicing medical oncologist and hematologist at Providence Regional Medical Center and with the Everett Clinic. Dr. Walker currently serves on the board of directors of Zentalis Pharmaceuticals, a public biopharmaceutical company. Dr. Walker received his M.D. from the University of Oklahoma College of Medicine. The Company has determined that Dr. Walker’s medical and business background make him a qualified member of our board of directors.

Linda West – Director

Ms. West has served as a member of our board of directors since March 2021. Ms. West served in multiple leadership roles of increasing responsibility for E. I. du Pont de Nemours and Company from 1981 until her retirement in November 2019. Ms. West most recently served as Vice President, Corporate Planning and Analyses, where she led the execution of transformational transactions from October 2009 until her retirement including major divestitures, spin-offs, acquisitions, and the merger with The Dow Company followed by simultaneous spin-offs into three independent companies. Throughout her career with DuPont, Ms. West had P&L accountabilities varying from late to early stage businesses including DuPont Imaging Technologies, DuPont Personal Protection, DuPont Microcircuit Materials, and DuPont Industrial Imaging. In addition, Ms. West was the Chief Financial Officer of multiple DuPont businesses and was the Vice President, General Auditor and Chief Ethics and Compliance Officer for five years during the initial implementation of the Sarbanes-Oxley Act of 2002. Ms. West previously served on the board of directors of Galera Therapeutics, Inc. Ms. West holds a B.S. in Accounting with a minor in Business Administration from the University of Delaware. The Company has determined that Ms. West’s business and finance background make her a qualified member of our board of directors.

Independence of the Board of Directors

As required under Nasdaq listing rules, a majority of the members of a listed company's board of directors must qualify as "independent," as affirmatively determined by the Company's board. The Board consults with the Company's counsel as it seeks to ensure that the Board's determinations are consistent with relevant securities and other laws and regulations regarding the definition of "independent," including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Our Board has undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning such director's background, employment and affiliations, including family relationships, our Board determined that all of the directors, other than Mr. Lehr, are "independent directors" as defined under current rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, our Board considered the current and prior relationships that each non-employee director has with our Company and all other facts and circumstances that our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director and the transactions involving them described above.

Board Leadership Structure

The Board has an independent Chair, Andy Pasternak, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Chair has substantial ability to shape the work of the Board. We believe that separation of the positions of Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs. In addition, we believe that having an independent Chair creates an environment that is more conducive to objective evaluation and oversight of management's performance, increasing management accountability and improving the ability of the Board to monitor whether management's actions are in the best interests of the Company and

Table of Contents

our stockholders. As a result, we believe that having an independent Chair can enhance the effectiveness of the Board as a whole.

Role of the Board in Risk Oversight

One of the Board's key functions is informed oversight of our risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for our Company. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and risk management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements. Our Nominating and Corporate Governance Committee monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the chairperson of each committee of the Board to report findings regarding material risk exposures to the Board as quickly as possible.

Meetings of the Board of Directors

The Board of Directors met 8 times during 2025. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member.

Each member of the Board is expected to attend the annual meeting of stockholders of the Company, but we do not currently have a policy relating to director attendance. For the Company’s 2025 Annual Meeting of Stockholders, all of the then-serving directors were in attendance.

Table of Contents

PROPOSAL 1

ELECTIONS OF DIRECTORS

General

As previously disclosed, following the Court’s approval of the Stipulated Judgment and our filing of the Certificate of Correction with the Delaware Secretary of State, (i) Article V, Section 2 of our Amended and Restated Certificate of Incorporation, which provided that our directors would serve for a term of three years, and (ii) Article VI, Section 1 of our Amended and Restated Certificate of Incorporation, which provided that our directors could be removed from office only for cause, were determined to be invalid and unenforceable and are no longer part of our Amended and Restated Certificate of Incorporation.

Accordingly, the term of office of the current members of our Board of Directors will expire at the Annual Meeting, with each serving until his or her successor is elected and qualified or until his or her earlier death, resignation or removal, and directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.

Each director elected at the Annual Meeting will serve as a member of our Board of Directors until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. Our Board of Directors has nominated, upon the recommendation of our Nominating and Corporate Governance Committee, Dr. Philip Kantoff, Martin Lehr, Andy Pasternak, Dr. Karen Smith, Jennifer Evans Stacey, Dr. Luke Walker and Linda West for re-election at the Annual Meeting, each to serve a one-year term expiring at our 2027 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. Each nominee is currently serving as a director. Mr. Pasternak, Dr. Smith and Dr. Walker were initially identified by our Chief Executive Officer as possible director candidates and recommended to the Nominating and Corporate Governance Committee. We expect each nominee will be able to serve if elected. If any nominee is unable to serve, proxies will be voted in favor of the remainder of those nominees and for such substitute nominee as may be selected by our Board of Directors.

Biographical information and the attributes, skills and experience of each nominee that led our Nominating and Corporate Governance Committee and Board of Directors to determine that such nominee should serve as a director are discussed in the "Information Regarding the Board of Directors and Corporate Governance" section of this proxy statement.

Directors will be elected by a plurality of the votes cast by the holders of our outstanding shares present in person or represented by proxy at the Annual Meeting and entitled to vote thereon. Accordingly, the seven director nominees receiving the highest number of “FOR” votes will be elected to our Board of Directors.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR ALL" ON PROPOSAL 1 TO ELECT DR. PHILIP KANTOFF, MARTIN LEHR, ANDY PASTERNAK, DR. KAREN SMITH, JENNIFER EVANS STACEY, DR. LUKE WALKER AND LINDA WEST.

Table of Contents

PROPOSAL 2

RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee of the Board has selected CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 and has further directed that management submit the selection of our independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. CohnReznick LLP has audited the Company’s financial statements since January 2021.

Representatives of CohnReznick LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our bylaws nor other governing documents or law require stockholder ratification of the selection of CohnReznick LLP as our independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of CohnReznick LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and our stockholders.

The affirmative vote of stockholders holding a majority of the voting power present in person or represented by proxy at the Annual Meeting and entitled to vote on this matter will be required to ratify the selection of CohnReznick LLP.

Principal Accountant Fees and Services

The following table represents aggregate fees billed to us for the fiscal years ended December 31, 2025 and 2024 by CohnReznick LLP:


	Year Ended December 31,
	2025		2024
Audit fees(1)	$	319,253	$	303,697
Audit-related fees	—		—
Tax fees	—		—
All other fees	—		—
Total fees	$	319,253	$	303,697

(1)Fees represent professional services related to our annual audit, quarterly review, SEC offerings, comfort letter and accounting consultations.

Pursuant to the Audit Committee charter, the Audit Committee is responsible for reviewing and approving in advance all audit and non-audit services to be performed by the independent accountants. These services may include audit services, audit-related services, tax services, and other non-audit services. As part of its pre-approval procedures, the Audit Committee considers whether the provision of any proposed non-audit services is consistent with the SEC’s rules on auditor independence. In accordance with the Audit Committee charter, the Audit Committee has pre-approved certain specified audit and non-audit services to be provided by our independent auditor. If there are any additional services to be provided, a request for pre-approval must be submitted to the Audit Committee for its consideration. The Audit Committee generally pre-approves particular services or categories of services on a case-by-case basis. Finally, in accordance with the Audit Committee charter, the Audit Committee has delegated pre-approval authority to the chair of the Audit Committee. The chair must report any pre-approval decisions to the Audit Committee at its next meeting.

All of the services provided by CohnReznick LLP for the years ended December 31, 2025 and 2024 described above were pre-approved in accordance with the Audit Committee charter.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 2.

Table of Contents

PROPOSAL 3

APPROVAL OF AN AMENDMENT TO THE COMPANY'S

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK

On March 18, 2026, the Board adopted, subject to stockholder approval, an amendment to Article IV, Section 1 of our Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of authorized shares of our common stock by 100,000,000 shares, or from 200,000,000 shares to 300,000,000 shares. The following discussion is qualified by the text of the Charter Amendment, which is set forth in Appendix A attached to this proxy statement. The Board believes that the Charter Amendment is necessary to maintain flexibility to issue shares of common stock for future corporate needs.

The additional authorized shares of common stock to be authorized by the Charter Amendment would have rights identical to our current issued and outstanding shares of common stock. Issuance of the additional shares of common stock would not affect the rights of the holders of our issued and outstanding shares of common stock, except for effects incidental to any increase in the number of shares of common stock issued and outstanding, such as dilution of earnings or loss per share and voting rights.

If the Charter Amendment is approved by stockholders at the Annual Meeting, then it will become effective upon filing of a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, which filing is expected to occur promptly following the Annual Meeting. The Board reserves the right, notwithstanding stockholder approval of the Charter Amendment and without further action by our stockholders, not to proceed with the Charter Amendment at any time before it becomes effective.

Pursuant to Section 242(d) of the DGCL, the affirmative vote of a majority of the votes cast for or against the Charter Amendment by the holders of our outstanding shares present in person or represented by proxy at the Annual Meeting and entitled to vote thereon will be required to approve the Charter Amendment.

Capitalization

Our Amended and Restated Certificate of Incorporation currently authorizes up to 210,000,000 shares of capital stock, of which 200,000,000 are shares of common stock and 10,000,000 are shares of preferred stock. As of April 13, 2026, we had no shares of preferred stock issued and outstanding and the Charter Amendment does not affect the number of authorized shares of preferred stock.

As of April 13, 2026, we estimate that the following shares of common stock were issued or reserved for future issuance:

•91,879,177 shares were issued and outstanding;

•8,099,074 shares were reserved for issuance upon the exercise of outstanding stock options;

•2,817,769 shares were reserved for future issuance under our 2021 Long-Term Performance Incentive Plan (the “2021 Incentive Plan”); and

•9,164,541 shares were reserved for issuance upon the exercise of outstanding warrants.

Accordingly, at April 13, 2026, 88,039,439 shares of common stock remained unreserved and available for future issuance. In consideration of the foregoing, the Board approved the Charter Amendment in substantially the form set forth in Appendix A and has recommended that our stockholders do the same.

Reasons for the Charter Amendment

We believe that the additional shares of authorized common stock under the Charter Amendment may be necessary to provide us with appropriate flexibility to utilize equity for business and financial purposes that the Board determines to be in our best interests on a timely basis without the expense and delay of a stockholders’ meeting. The Board believes that the currently remaining authorized common stock may not be sufficient to permit us to respond to potential business opportunities, to pursue important objectives designed to enhance stockholder value, and to recruit and retain employees, directors, officers and consultants.

Table of Contents

The additional authorized shares of common stock under the Charter Amendment are expected to provide us with flexibility to use our common stock, without further stockholder approval (except to the extent such approval may be required by law or by applicable exchange listing standards) for any proper corporate purposes, including, without limitation, raising capital through one or more future public offerings or private placements of equity securities, expanding our business, acquisition transactions, entering into strategic relationships, providing equity-based compensation and/or incentives to employees, consultants, officers and directors, effecting stock dividends or for other general corporate purposes. The Board will determine whether, when and on what terms the issuance of shares of common stock may be warranted in connection with any of the foregoing purposes.

If the Charter Amendment is not approved by our stockholders, our business development and financing alternatives may be limited by the lack of sufficient unissued and unreserved authorized shares of common stock, and stockholder value may be harmed by this limitation. In addition, our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel, and if the Charter Amendment is not approved by our stockholders, we may not have sufficient unissued and unreserved authorized shares of common stock to provide the future equity incentive opportunities that our Compensation Committee deems appropriate. In summary, if our stockholders do not approve the Charter Amendment, we may not be able to access the capital markets, initiate or complete future clinical trials and other key development activities, complete corporate collaborations or partnerships, attract, retain and motivate employees and others required to make our business successful, and pursue other business opportunities integral to our growth and success, all of which could harm our Company and our prospects.

Other than shares related to future awards under the 2021 Incentive Plan, outstanding awards issued pursuant to the 2021 Incentive Plan, prior equity compensation plans or inducement awards issued outside of the 2021 Incentive Plan, and outstanding warrants, we do not currently have any other arrangements, agreements or understandings that would require the issuance of additional shares of our common stock. Because it is anticipated that our directors and executive officers will be granted additional equity awards under the 2021 Incentive Plan, they may be deemed to have an indirect interest in the Charter Amendment, because absent the Charter Amendment, we may not have sufficient authorized shares to grant such awards in the future.

Possible Effects of the Amendment

The increase in authorized shares of our common stock under the Charter Amendment will not have any immediate effect on the rights of existing stockholders. However, because the holders of our common stock do not have any preemptive rights, future issuance of shares of common stock or securities exercisable for or convertible into shares of common stock could have a dilutive effect on our earnings or loss per share, book value per share, voting rights of stockholders and could have a negative effect on the price of our common stock.

The Board has not proposed the increase in the number of authorized shares of common stock with the intent of using the additional shares to prevent or discourage any actual or threatened takeover of our Company. Under certain circumstances, however, the additional authorized shares could be used in a manner that has an anti-takeover effect. For example, the additional shares could be used to dilute the stock ownership or voting rights of persons seeking to obtain control of our Company or could be issued to persons allied with the Board or management and thereby have the effect of making it more difficult to remove directors or members of management by diluting the stock ownership or voting rights of persons seeking to effect such a removal. Accordingly, if the Charter Amendment is approved by stockholders, the additional shares of authorized common stock may render more difficult or discourage a merger, tender offer or proxy contest, the assumption of control by a holder or group of holders of a large block of common stock, or the replacement or removal of one or more directors or members of management.

The following other provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, in combination with the additional authorized shares, may also have an anti-takeover effect of preventing or discouraging a change in control of our Company: (i) authorizing the Board to issue preferred stock from time to time, in one or more classes or series, without stockholder approval; (ii) requiring the approval of at least two-thirds of the total voting power of our outstanding voting securities to amend specified provisions of our Amended and Restated Bylaws; (iii) requiring the approval of a majority of our total number of authorized directors and at least two-thirds of the total voting power of our outstanding voting securities to amend specified provisions of our Amended and Restated Certificate of Incorporation; (iv) providing that special meetings of our stockholders may be called only by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors, the chairperson of the Board, our Chief Executive Officer or our President; (v) providing that vacancies on the Board and newly created directorships may be filled

Table of Contents

only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not by stockholders; and (vi) the absence of cumulative voting rights in the election of directors.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 3.

Table of Contents

PROPOSAL 4

APPROVAL OF THE ADJOURNMENT PROPOSAL

We are asking our stockholders to approve a proposal to approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Annual Meeting (“Adjournment Proposal”). If our stockholders approve this Adjournment Proposal, we could adjourn the Annual Meeting and any reconvened session of the Annual Meeting and use the additional time to solicit additional proxies, including the solicitation of proxies from stockholders that have previously returned properly executed proxies voting against approval of Proposal 3. Among other things, approval of the Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of votes against approval of Proposal 3 such that the proposal would be defeated, we could adjourn the Annual Meeting without a vote on the approval of Proposal 3 and seek to convince the holders of those shares to change their votes to votes in favor of approval of Proposal 3.

Additionally, we may seek to adjourn the Annual Meeting if the quorum required by Nasdaq Listing Rules is not present at the Annual Meeting. Although, pursuant to an order of the Delaware Court of Chancery, the shares of stock represented at the Annual Meeting, either in person or by proxy, and entitled to vote thereat, shall constitute a quorum, notwithstanding any provision of our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws to the contrary, pursuant to Nasdaq Listing Rule 5620(c), we are not permitted to utilize a quorum that is less than 33 1/3% of our outstanding shares of common stock for any stockholder meeting. As a result, although we intend to initially convene and hold the Annual Meeting on June 24, 2026, in order to remain compliant with the Nasdaq Listing Rules in the event that holders of 33 1/3% of our outstanding shares of common stock are not initially present at the Annual Meeting, we intend to adjourn the Annual Meeting one or more times as necessary until stockholders holding at least 33 1/3% of our outstanding shares of common stock as of the record date are present at the Annual Meeting by remote communication or represented by proxy.

The Board believes that it is in the best interests of our Company and our stockholders to be able to adjourn the Annual Meeting to a later date or dates if necessary or appropriate for the purpose of soliciting additional proxies in respect of the approval of Proposal 3 if there are insufficient votes to approve such proposal at the time of the Annual Meeting.

The affirmative vote of stockholders holding a majority of the voting power of the shares present in person or represented

by proxy at the Annual Meeting and entitled to vote on this matter will be required to adjourn the Annual Meeting.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 4.

EXECUTIVE OFFICERS

The following table sets forth information concerning our executive officers as of the date of this proxy statement.

Name

Age

Title

Martin Lehr

Director, President and Chief Executive Officer

Karen Chagin, MD

Chief Medical Officer

Alex Levit

Chief Legal Officer and Corporate Secretary

Jennifer Minai-Azary

Chief Financial Officer and Treasurer

Martin Lehr Biographical information for Mr. Lehr is included above with the director biographies under the caption "Information Regarding the Board of Directors and Corporate Governance."

Karen Chagin, MD. Dr. Chagin joined Context in June 2025 as Chief Medical Officer. Prior to joining Context, Dr. Chagin served as Senior Vice President of Early-Stage Development at Adaptimmune Therapeutics plc, a public biotechnology company. Prior to Adaptimmune, Dr. Chagin held positions of increasing responsibility at Tmunity Therapeutics, a private biotechnology company, from 2019 to 2023, ultimately becoming Chief Medical Officer, and the Head of Kite Philadelphia following Kite Pharma’s acquisition of Tmunity. From 2015 to 2019, Dr. Chagin served as Adaptimmune’s Vice President of Clinical Development. Prior to joining Adaptimmune in 2015, she served as a Scientific Director in Oncology Early Development at Janssen leading development activities for Phase 1 assets. Dr. Chagin began her career in the pharmaceutical industry in 2009 at GSK and served as a Safety Development leader before transitioning to clinical development. Dr. Chagin holds a B.A from the University of Pennsylvania and an M.D. from Temple University

Table of Contents

School of Medicine. She performed her residency at Children’s Memorial Hospital in Chicago and her fellowship in pediatric hematology and oncology at The Children’s Hospital of Philadelphia.

Alex Levit Mr. Levit joined Context in April 2021 as Chief Legal Officer and serves as Corporate Secretary. Prior to joining the Company, Mr. Levit served as Vice President, Deputy General Counsel and Assistant Corporate Secretary, as well as Associate General Counsel and Assistant Secretary of OptiNose, a publicly-traded specialty pharmaceutical company, from 2017 until 2021. Prior to OptiNose, Mr. Levit served as Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company, from 2010 until 2017. During his tenures at OptiNose and Teva, Mr. Levit negotiated various in-bound and out-bound licenses, collaborations, mergers and acquisitions, and supply agreements. While at OptiNose, Mr. Levit also handled various public and private financing transactions. Before joining Teva, Mr. Levit was a corporate and life sciences attorney at the law firm of Reed Smith LLP. Mr. Levit also serves as a member of the board of directors of Strados Labs, Inc., a medical technology company. Mr. Levit holds a J.D. from Temple University Beasley School of Law and a B.A. in Labor & Industrial Relations from Pennsylvania State University, where he is a graduate of the Schreyer Honors College.

Jennifer Minai-Azary Ms. Minai-Azary joined Context in November 2021 as Chief Financial Officer and Treasurer. She brings more than 25 years of finance and accounting experience and has spent the past decade leading finance teams within the life sciences industry. Ms. Minai-Azary also serves on the board of directors of KAHR Medical Ltd., a clinical stage company developing immune recruiting therapies to treat cancer. Prior to joining the Company, Ms. Minai-Azary served as Chief Financial Officer of Millendo Therapeutics, now Tempest Therapeutics, a publicly-traded biopharmaceutical company. She also served as Vice President, Finance, as well as in other finance roles, at Millendo where she was responsible for the financial reporting, accounting, treasury, tax, and risk management functions. While at Millendo, she played a key role in several financing transactions and company mergers. Before that, she served as Director, Technical Accounting at PAREXEL International. Ms. Minai-Azary began her career at Ernst & Young and held positions of increasing responsibility where she managed financial statement audits for publicly-traded and privately-held clients within a variety of industries. Ms. Minai-Azary holds a Master of Accounting and a B.B.A. from the University of Michigan.

Table of Contents

SECURITY OWNERSHIP OF

CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth the beneficial ownership of our common stock as of April 13, 2026 for:

•each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock;

•each of our named executive officers;

•each of our directors; and

•all of our current executive officers and directors as a group.

Except, as otherwise noted below, the percentage ownership information shown in the table below is based upon 91,879,177 shares of common stock outstanding as of April 13, 2026.

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, these rules require that we include shares of common stock issuable pursuant to the vesting of restricted stock units and the exercise of stock options and warrants that are either immediately exercisable or exercisable within 60 days of April 13, 2026. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

Except as otherwise noted below, the address for persons listed in the table is c/o Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103.


	Beneficial Ownership
	Common Stock
	Shares	%
Named Executive Officers and Directors
Martin Lehr(1)	2,257,862	2.4	%
Jennifer Minai-Azary(2)	576,526	*
Alex Levit(3)	559,036	*
Andy Pasternak (4)	159,585	*
Jennifer Evans Stacey, Esq.(5)	213,500	*
Philip Kantoff(6)	217,031	*
Karen Smith(7)	142,815	*
Luke Walker(8)	142,815	*
Linda West(9)	213,500	*
All current executive officers and directors as a group (10 persons)	4,520,920	4.8	%
Greater than 5% Holders
MPM BioImpact LLC (10)	10,679,391	11.6	%
Avidity Private Master Fund I LP(11)	9,200,580	9.9	%
Deep Track Capital, LP(12)	7,419,355	8.1	%
Nextech Crossover I SCSp(13)	7,419,355	8.1	%
Blue Owl Capital Holdings LP(14)	6,357,928	6.9	%
Soleus Capital Master Fund, L.P.(15)	4,776,398	5.2	%
Great Point Partners, LLC(16)	4,683,711	5.1	%

*Represents beneficial ownership of less than 1%.

(1)Consists of (i) 1,079,891 shares of common stock (of which 920,190 shares of common stock are held by the Martin Lehr 2000 Trust, for which Ellyn Lehr is the Trustee); and (ii) 1,177,971 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(2)Consists of (i) 80,010 shares of common stock; and (ii) 496,516 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

Table of Contents

(3)Consists of (i) 29,000 shares of common stock; (ii) 477,053 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026, and (iii) 52,983 shares of common stock owned by Mr. Levit’s spouse.

(4)Consists of 159,585 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(5)Consists of 213,500 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(6)Consists of (i) 3,531 shares of common stock; and (ii) 213,500 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(7)Consists of 142,815 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(8)Consists of 142,815 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(9)Consists of 213,500 shares of common stock issuable upon exercise of stock options that are exercisable within 60 days of April 13, 2026.

(10)Based solely on the information reported in a Schedule 13G/A filed by MPM BioImpact LLC (“MPM BioImpact”) on February 17, 2026 with the SEC. As reported in the filing, MPM BioIpmact has sole voting and dispositive power with respect to 10,679,391 shares of common stock and shared voting and dispositive power with respect to no shares of common stock. The principal address for MPM BioImpact is 399 Boylston Street, Suite 1100, Boston, MA 02116.

(11)Based solely on the information reported in a Schedule 13G/A filed by Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, Avidity Private Master Fund I LP and Michael Gregory (collectively, the “Avidity Parties”) on November 14, 2025 with the SEC. As reported in the filing, the Avidity Parties have sole voting and dispositive power with respect to no shares of common stock. Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, and Mr. Gregory have shared voting and dispositive power with respect to 9,200,580 shares of common stock, Avidity Master Fund LP has shared voting and dispositive power with respect to 4,510,100 shares of common stock, and Avidity Private Master Fund I LP has shared voting and dispositive power with respect to 7,776,296 shares of common stock. The percentage ownership in the table above is as reported in the Schedule 13G/A filed by the Avidity Parties on November 14, 2025 with the SEC. Mr. Gregory is the managing member of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP) LLC. The principal address for the Avidity Parties is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201.

(12)Based solely on the information reported in a Schedule 13G/A filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin (collectively, the “Deep Track Parties”) on May 15, 2025 with the SEC. As reported in the filing, the Deep Track Parties have sole voting and dispositive power with respect to no shares of common stock and shared voting and dispositive power with respect to 7,419,355 shares of common stock. Mr. Kroin is the Managing Member of Deep Track Capital GP LLC, which is the General Partner of Deep Track Capital, LP. The principal address for Deep Track Capital, LP and David Kroin is 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830, and the principal address for Deep Track Biotechnology Master Fund, Ltd. is c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands.

(13)Based solely on the information reported in a Schedule 13G filed by Nextech Crossover I SCSp, Nextech Crossover I GP S.à r.l., Ian Charoub, Costas Constantinides and Rocco Sgobbo (the “Nextech Parties”) on May 24, 2024 with the SEC. As reported in the filing, Nextech Crossover I SCSp and Nextech Crossover I GP S.à r.l. have sole voting and dispositive power with respect to 7,419,355 shares of common stock and shared voting and dispositive power with respect to no shares of common stock. Ian Charoub, Costas Constantinides and Rocco Sgobbo have sole voting and dispositive power with respect to no shares of common stock and shared voting and dispositive power with respect to 7,419,355 shares of common stock. Messrs. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover I GP S.à r.l. The principal address for the Nextech Parties is 8 rue Lou Hemmer, L-1748 Luxembourg-Findel, Grand-Duché de Luxembourg.

(14)Based solely on the information reported in a Schedule 13G/A filed by Blue Owl Capital Holdings LP (“Blue Owl”) on February 14, 2025 with the SEC. As reported in the filing, Blue Owl has sole voting and dispositive power with respect to 6,357,928 shares of common stock and shared voting and dispositive power with respect to no shares of common stock. The principal address for Blue Owl is 399 Park Avenue, New York, New York 10022.

(15)Based solely on the information reported in a Schedule 13G filed by Soleus Capital Master Fund, L.P. (“Master Fund”), Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy (collectively, the “Soleus Parties”) on February 3, 2026. As reported in the filing, the Soleus Parties have sole voting and dispositive power with respect to no shares of common stock and shared voting and dispositive power with respect to 4,776,398 shares of common stock. Soleus Capital, LLC is the sole general partner of Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Soleus Capital Management, L.P. is the investment manager for Master Fund. Soleus GP, LLC is the sole general partner of Soleus Capital Management, L.P. Guy Levy is the sole managing member of Soleus Capital Group, LLC and Soleus GP, LLC. The principal address for the Soleus Parties is 100 Field Point Road, Suite 200, Greenwich, CT 06830.

(16)Based solely on the information reported in a Schedule 13G/A filed by Great Point Partners, LLC, Jeffrey R. Jay, M.D. and Lillian Nordahl (the “Great Point Parties”) on February 17, 2026 with the SEC. As reported in the filing, the Great Point Parties have sole voting and dispositive power with respect to no shares of common stock and shared voting and dispositive power with respect to 4,683,711 shares of common stock. Dr. Jay is the Senior Managing Member of Great Point Partners, LLC, and Ms. Nordahl is the Managing Director of Great Point Partners, LLC. The principal address for the Great Point Parties is 165 Mason Street, 3rd Floor, Greenwich, CT 06830.

Table of Contents

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table sets forth information regarding compensation earned with respect to the years ended December 31, 2025 and 2024 by our named executive officers, which include our principal executive officer and the next two most highly compensated executive officers in 2025.


Name and Principal Position	Year	Salary ($)	Bonus ($)(1)	Option Awards ($)(2)	Non-Equity Incentive Plan Compensation ($)(3)	All Other Compensation ($)	Total ($)
Martin Lehr Chief Executive Officer	2025	588,515	15,000	551,415	300,000	10,500	1,465,430
	2024	506,268	10,163	245,473	238,815	10,350	1,011,069
Alex Levit Chief Legal Officer and Corporate Secretary	2025	397,807	8,000	240,364	160,000	10,500	816,671
	2024	381,062	6,119	129,319	143,803	10,350	670,653
Jennifer Minai-Azary Chief Financial Officer and Treasurer	2025	421,731	8,500	255,408	170,000	10,500	866,139
	2024	397,393	6,381	134,878	149,966	10,350	698,968

_______________________________

(1)Represents the discretionary portion of 2025 and 2024 bonus payments to the named executive officers.

(2)In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during the applicable year computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions ("ASC 718"). Assumptions used in the calculation of these amounts are included in Note 7 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. These amounts do not reflect the actual economic value that may be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.

(3)See “Employment, Severance and Change in Control Agreements—2025 Bonus Opportunity” below for a description of the material terms of the programs pursuant to which this compensation to our named executive officers was awarded.

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth certain information about equity awards granted to our named executive officers that remained outstanding as of December 31, 2025.


		Option Awards
Name and Principal Position		Grant Date		Number of Securities Underlying Unexercised Options Exercisable (#)	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date
Martin Lehr Chief Executive Officer	(2)	4/30/2021	(3)	281,354	—	4.94	4/30/2031
	(2)	2/25/2022	(5)	243,704	10,596	1.79	2/24/2032
	(2)	2/13/2023	(6)	203,677	83,867	0.84	2/12/2033
	(2)	3/21/2024	(7)	127,488	163,914	1.07	3/20/2034
	(2)	2/13/2025	(8)	—	802,700	0.81	2/12/2035
Alex Levit Chief Legal Officer and Secretary	(1)	5/2/2020		833	—	5.70	5/2/2030
	(2)	4/30/2021	(3)	52,754	—	4.94	4/30/2031
	(2)	2/25/2022	(5)	103,375	4,495	1.79	2/24/2032
	(2)	2/13/2023	(6)	107,316	44,189	0.84	2/12/2033
	(2)	3/21/2024	(7)	67,163	86,352	1.07	3/20/2034
	(2)	2/13/2025	(8)	—	349,900	0.81	2/12/2035
Jennifer Minai-Azary Chief Financial Officer and Treasurer	(2)	11/1/2021	(4)	52,753	—	5.59	11/1/2031
	(2)	2/25/2022	(5)	107,784	4,686	1.79	2/24/2032
	(2)	2/13/2023	(6)	111,917	46,084	0.84	2/12/2033
	(2)	3/21/2024	(7)	70,050	90,065	1.07	3/20/2034
	(2)	2/13/2025	(8)	—	371,800	0.81	2/12/2035

_______________________________

(1)Previously granted under the Context Therapeutics LLC 2015 Stock Option Plan, which was substituted for a substantially equivalent grant under the Context Therapeutics Inc. 2021 Incentive Plan.

(2)Granted under the Context Therapeutics Inc. 2021 Incentive Plan.

(3)The shares of common stock underlying this option vested and became exercisable in equal monthly installments over 36 months from the date of grant on April 30, 2021, subject to the recipient’s continued service through each vesting date.

(4)The shares of common stock underlying this option vested and became exercisable in equal monthly installments over 36 months from the date of grant on November 1, 2021, subject to the recipient’s continued service through each vesting date.

(5)The shares of common stock underlying this option vested and became exercisable 25% on February 25, 2023 (the first anniversary of the grant date), and the balance vested and became exercisable in equal monthly installments over the following three years, subject to the recipient’s continued service through each vesting date.

(6)The shares of common stock underlying this option vested and became exercisable 25% on February 13, 2024 (the first anniversary of the grant date), and the balance will vest and become exercisable in equal monthly installments over the following three years, subject to the recipient’s continued service through each vesting date.

(7)The shares of common stock underlying this option vested and became exercisable 25% on March 21, 2025 (the first anniversary of the grant date), and the balance will vest and become exercisable in equal monthly installments over the following three years, subject to the recipient’s continued service through each vesting date.

(8)The shares of common stock underlying this option vested and became exercisable 25% on February 13, 2026 (the first anniversary of the grant date), and the balance will vest and become exercisable in equal monthly installments over the following three years, subject to the recipient’s continued service through each vesting date.

See “Employment, Severance and Change in Control Agreements—Potential Payments upon Termination or Change of Control” for a description of vesting acceleration applicable to stock options held by our named executive officers.

Table of Contents

We may in the future, on an annual basis or otherwise, grant additional equity awards to our executive officers pursuant to the Context Therapeutics Inc. 2021 Incentive Plan.

Employment, Severance and Change in Control Agreements

Employment Arrangements

Each of our named executive officers’ employment is “at will” and may be terminated at any time. Below is a description of our employment agreements with each of our named executive officers.

Martin Lehr We entered into an amended and restated employment agreement with Mr. Lehr in October 2021, setting forth the terms of his employment (the “Lehr Employment Agreement”). Under the terms of the Lehr Employment Agreement, Mr. Lehr was entitled to an initial annual base salary of $465,000, which was subsequently increased, most recently to $635,000 effective February 16, 2026. The Lehr Employment Agreement also provides that Mr. Lehr is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 50% of his base salary, which was subsequently increased to 55%, effective for the 2026 calendar year bonus. The actual amount of any such bonus is determined at the sole discretion of our Board based upon its assessment of Mr. Lehr’s performance and Company performance. In addition, the Lehr Employment Agreement provides for certain severance and change in control-related payments and benefits, the terms of which are described below under “—Potential Payments upon Termination or Change of Control.”

Alex Levit We entered into an employment agreement with Mr. Levit in October 2021, setting forth the terms of his employment. Under the terms of the employment agreement, Mr. Levit was entitled to an initial annual base salary of $350,000, which was subsequently increased, most recently to $430,000 effective February 16, 2026. The employment agreement also provides that Mr. Levit is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 40% of his base salary. The actual amount of any such bonus is determined at the sole discretion of the Compensation Committee of our Board based upon its assessment of Mr. Levit’s performance and Company performance. In addition, Mr. Levit’s employment agreement provides for certain severance and change in control-related payments and benefits, the terms of which are described below under “—Potential Payments upon Termination or Change of Control.”

Jennifer Minai-Azary We entered into an employment agreement with Ms. Minai-Azary in November 2021, setting forth the terms of her employment. Under the terms of the employment agreement, Ms. Minai-Azary was entitled to an initial annual base salary of $365,000, which was subsequently increased, most recently to $460,000 effective February 16, 2026. The employment agreement also provides that Ms. Minai-Azary is eligible to receive a discretionary annual performance-based cash bonus, with a target bonus amount equal to 40% of her base salary. The actual amount of any such bonus is determined at the sole discretion of the Compensation Committee of our Board based upon its assessment of Ms. Minai-Azary’s performance and Company performance. In addition, Ms. Minai-Azary’s employment agreement provides for certain severance and change in control-related payments and benefits, the terms of which are described below under “—Potential Payments upon Termination or Change of Control.”

2025 Bonus Opportunity

Each of our named executive officers was eligible to receive a bonus in 2025. The bonus opportunity was designed to motivate and reward our named executive officers for the attainment of company-wide performance goals, including the achievement of clinical development, financial, business development and other corporate objectives; however, the Compensation Committee, or the Board with respect to Mr. Lehr, retains discretion to allow for individual adjustments based on such factors as it deems appropriate. The 2025 target bonus amounts were set as a percentage of the named executive officer’s annual base salary for 2025 as follows: (1) Mr. Lehr’s target bonus percentage was set at 50%, and (2) Ms. Minai-Azary and Mr. Levit’s target bonus percentages were each set at 40%. Our named executive officers for 2025 were eligible to receive more than 100% of their target bonuses in the discretion of our Compensation Committee, or our Board with respect to Mr. Lehr. Bonuses were measured as of December 31, 2025, and the Compensation Committee, or our Board with respect to Mr. Lehr, determined that performance goals under the 2025 bonus plan were achieved at a 100% level. The Compensation Committee, or our Board with respect to Mr. Lehr, also granted each named executive officer a discretionary bonus equal to 5% of his or her target bonus amount in connection, in part, with the Company’s progress on its clinical and preclinical programs, which resulted in a total bonus payout of 105% of target. The bonuses were paid in the first quarter of 2026. For 2025, Mr. Lehr’s actual bonus amount was $315,000, Mr. Levit’s actual bonus amount was $168,000, and Ms. Minai-Azary’s actual bonus amount was $178,500.

Table of Contents

2026 Bonus Opportunity

In 2026, each of our named executive officers is eligible to receive a bonus. The bonus opportunity is designed to motivate and reward our named executive officers for the attainment of company-wide goals, including the achievement of clinical development, financial, business development and other corporate objectives; however, the Compensation Committee, or the Board with respect to Mr. Lehr, retains discretion to allow for individual adjustments based on such factors as it deems appropriate. Consistent with prior years, the 2026 performance bonus amounts were set as a percentage of each named executive officer’s annual base salary for 2026 as follows: (1) Mr. Lehr’s target bonus percentage was increased to 55% and (2) Ms. Minai-Azary and Mr. Levit’s target bonus percentages remained unchanged at 40%. The named executive officers are eligible to receive more than 100% of their target bonuses in the discretion of our Compensation Committee, or our Board with respect to Mr. Lehr.

Potential Payments upon Termination or Change of Control

Mr. Lehr. Pursuant to the Lehr Employment Agreement, Mr. Lehr will be entitled to receive the following severance benefits if Mr. Lehr’s employment is terminated by the Company without “cause” or by Mr. Lehr for “good reason” (each as defined in the Lehr Employment Agreement), subject to his execution and non-revocation of a release of claims and compliance with the restrictive covenants set forth in the Lehr Employment Agreement: (i) twelve months of base salary continuation, (ii) up to twelve months of continued participation by Mr. Lehr and his eligible dependents in the Company’s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, (iii) any earned but unpaid performance-based annual incentive bonus for any completed fiscal year preceding such termination, and (iv) all unvested options and any other unvested incentive equity awards granted to him by the Company that are scheduled to vest within eighteen months after such termination shall immediately vest; and, provided that if such termination of employment occurs within twelve months after a “change in control,” (as defined in the Lehr Employment Agreement), then Mr. Lehr shall be entitled to receive: (i) an amount equal to 150% of his annual base salary at the rate in effect on his date of termination, payable ratably over an eighteen month period, (ii) an amount equal to 100% of his target bonus opportunity for the fiscal year in which the Termination Date (as defined in the Lehr Employment Agreement) occurs, payable ratably over a twelve month period, (iii) up to twelve months of continued participation by Mr. Lehr and his eligible dependents in the Company’s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, (iv) any earned but unpaid performance-based annual incentive bonus for any completed fiscal year preceding such termination, and (v) all unvested options and any other unvested incentive equity awards granted to him by the Company will become immediately vested.

Ms. Minai-Azary and Mr. Levit Pursuant to the employment agreements with each of Ms. Minai-Azary and Mr. Levit (the “Non-CEO Executives”), each Non-CEO Executive will be entitled to receive the following severance benefits if such Non-CEO Executive’s employment is terminated by the Company without “cause” or by such Non-CEO Executive for “good reason” (each as defined in the employment agreement between the Company and each such Non-CEO Executive (each, the “Non-CEO Executive Employment Agreement”)), subject to his or her execution and non-revocation of a release of claims and compliance with the restrictive covenants set forth in the Non-CEO Executive Employment Agreement: (i) nine months of base salary continuation, (ii) up to twelve months of continued participation by such Non-CEO Executive and his or her eligible dependents in the Company’s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, (iii) any earned but unpaid performance-based annual incentive bonus for any completed fiscal year preceding such termination, and (iv) all unvested options and any other unvested incentive equity awards granted to him or her by the Company that are scheduled to vest within twelve months after such termination shall immediately vest; and, provided that if such termination of employment occurs within twelve months after a “change in control,” (as defined in the Non-CEO Executive Employment Agreement), then such Non-CEO Executive shall be entitled to receive: (i) an amount equal to 100% of his or her annual base salary at the rate in effect on his or her date of termination, payable ratably over a twelve month period, (ii) an amount equal to 100% of his or her target bonus opportunity for the fiscal year in which the Termination Date (as defined in the Non-CEO Executive Employment Agreement) occurs, payable ratably over a twelve month period, (iii) up to twelve months of continued participation by such Non-CEO Executive and his or her eligible dependents in the Company’s standard group medical, vision and dental plans on substantially the same terms as such benefits are provided to active employees, (iv) any earned but unpaid performance-based annual incentive bonus for any completed fiscal year preceding such termination, and (v) all unvested options and any other unvested incentive equity awards granted to him or her by the Company will become immediately vested.

401(k) Plan

Effective January 1, 2022, we maintain a defined contribution retirement plan (the "401(k) plan"), that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees may defer eligible

Table of Contents

compensation on a pre-tax basis, up to the statutorily prescribed annual limits on contributions under the Internal Revenue Code of 1986, as amended (the "Code"). Contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the participants' directions. We contribute a safe harbor minimum contribution equivalent to 3% of employees’ eligible compensation. Employees are immediately and fully vested in their contributions. The 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan's related trust intended to be tax exempt under Section 501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan.

Policies and Procedures Related to the Grant of Certain Equity Awards

We have established processes designed to ensure that the timing of any option grants and other awards to executive officers is not influenced by material nonpublic information (“MNPI”), and grants are generally made on a predetermined schedule, usually in February of each year, regardless of any upcoming announcements or events that could impact our share price. The Compensation Committee carefully reviews any potential MNPI before granting options and may delay a grant if necessary to avoid any appearance of impropriety related to the timing of the award.

Table of Contents

DIRECTOR COMPENSATION

The following table sets forth information regarding the compensation earned for service on our Board during the year ended December 31, 2025 by our directors who were not also our employees during 2025. Martin Lehr, our President and Chief Executive Officer, is also a member of our Board, but did not receive any additional compensation for service as a director. The compensation for Mr. Lehr as an executive officer is set forth above under “Executive Compensation- Summary Compensation Table.”


Name	Fees Earned or Paid in Cash ($)	Option Awards(1)(2) ($)	All Other Compensation		Total ($)
Richard Berman(3)	2,339	—	20,000	(4)	22,339
Philip Kantoff, MD	43,776	67,359	—		111,135
Andy Pasternak	65,739	93,288	—		159,027
Karen Smith, MD	49,558	67,359	83,332	(5)	200,249
Jennifer Evans Stacey, Esq.	55,276	67,359	—		122,635
Luke Walker, MD	43,776	67,359	—		111,135
Linda West	60,000	67,359	—		127,359

__________________________

(1)In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during 2025 computed in accordance with FASB ASC Topic 718. The assumptions we used in valuing the option awards are described in Note 7 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The aggregate grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. These amounts do not reflect the actual economic value that will be realized by the directors upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such stock options.

(2)The table following these footnotes shows the aggregate number of option awards and stock awards outstanding for each of our non-employee directors as of December 31, 2025.

(3)Mr. Berman’s resignation from the Board was effective as of January 13, 2025.

(4)Reflects compensation paid to Mr. Berman for consulting services after his resignation.

(5)Reflects $33,333 of compensation paid to Dr. Smith for her service as interim Chief Medical Officer of the Company and $49,999 for her subsequent service as a consultant to support the transition to our next Chief Medical Officer.


Name	Option Awards (#)	Stock Awards (#)
Richard Berman	—	—
Philip Kantoff, MD	213,500	—
Andy Pasternak	159,585	—
Karen Smith, MD, PhD, MBA, LLM	142,815	—
Jennifer Evans Stacey, Esq.	213,500	—
Luke Walker, MD	142,815	—
Linda West	213,500	—

Table of Contents

Non-Employee Director Compensation

Our Board approved an adjustment to our non-employee director compensation, which became effective as of February 19, 2026 for equity compensation and as of July 1, 2026 for cash compensation, pursuant to which our non-employee directors now receive the following:

• an annual cash retainer of $70,000 for the chairman of our Board;

• an annual cash retainer of $40,000 for the other members of our Board;

• an additional cash retainer of $15,000 for the Audit Committee chair, $12,000 for the Compensation Committee chair and $10,000 for the Nominating and Corporate Governance Committee chair;

• an additional cash retainer of $7,500 for non-chair members of the Audit Committee, $6,000 for non-chair members of the Compensation Committee and $5,000 for non-chair members of the Nominating and Corporate Governance Committee; and

• for members of our Board, (i) upon initiation of service, an initial grant of options to purchase 90,000 shares of our common stock pursuant to the 2021 Incentive Plan, which options vest one-third after the first year of Board service and one-third thereafter after each of the second and third years of Board service, subject to continued service with us, and (ii) an annual grant of options to purchase 45,000 shares of our common stock pursuant to the 2021 Incentive Plan, which options vest upon the earlier of (A) the first anniversary of the grant date or (B) the date of our next annual meeting of stockholders, subject to continued service with us. New directors whose service begins on or after January 1 and prior to that year’s annual meeting of stockholders shall not be eligible to receive an annual grant of options during such year.

Effective as of our 2025 Annual Meeting of Stockholders, our Board approved an adjustment to our non-employee director compensation, pursuant to which our non-employee directors received, or in the case of cash compensation, continued to receive, the following:

• an annual cash retainer of $55,000 for the chairman of our Board;

• an annual cash retainer of $40,000 for the other members of our Board;

• an additional cash retainer of $15,000 for the Audit Committee chair, $11,000 for the Compensation Committee chair and $8,000 for the Nominating and Corporate Governance Committee chair;

• an additional cash retainer of $7,500 for non-chair members of the Audit Committee, $5,000 for non-chair members of the Compensation Committee and $4,000 for non-chair members of the Nominating and Corporate Governance Committee; and

• for members of our Board, an annual grant of options to purchase a targeted fair value of approximately $120,000 of our common stock ($15,000 additional for our Board chair) pursuant to the 2021 Incentive Plan, which options vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of our next annual meeting of stockholders, subject to continued service with us.

Prior to the update effective as of our 2025 Annual Meeting of Stockholders to our non-employee director compensation, our non-employee directors received the following:

• an annual cash retainer of $55,000 for the chairman of our Board;

• an annual cash retainer of $40,000 for the other members of our Board;

• an additional cash retainer of $15,000 for the Audit Committee chair, $10,000 for the Compensation Committee chair and $7,500 for the Nominating and Corporate Governance Committee chair;

• an additional cash retainer of $7,500 for members of the Audit Committee, $5,000 for members of the Compensation Committee and $3,500 for members of the Nominating and Corporate Governance Committee; and

• for members of our Board, an annual grant of options to purchase 25,000 shares of our common stock (50,000 for our Board chair) pursuant to the Plan, which options vested upon the earlier of (i) the first anniversary of the grant date or (ii) the date of our next annual meeting of stockholders, subject to continued service with us.

Table of Contents

The annual cash compensation amounts set forth above are payable in equal quarterly installments, payable in arrears following the end of each calendar quarter in which the Board service occurs, prorated for any partial years of service. We also reimburse all reasonable out-of-pocket travel expenses incurred by non-employee directors in attending meetings of our Board or any committee thereof.

Director Independence

Our Board has undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning such director’s background, employment and affiliations, including family relationships, our Board determined that all of the directors, other than Mr. Lehr, are “independent directors” as defined under current rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, our Board considered the current and prior relationships that each non-employee director has or had with our Company and all other facts and circumstances that our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director and the transactions involving them described above.

In making its determination with respect to Dr. Smith, the Board considered Dr. Smith’s service as our interim Chief Medical Officer and as a consultant to support the transition to our next Chief Medical Officer. After reviewing the terms of these transactions, the Board determined they would not interfere with Dr. Smith’s exercise of independent judgment in carrying out her responsibilities as a director.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information with respect to our equity compensation plans in effect as of December 31, 2025:


Name	Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights (a)(#)	Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights (b)($)		Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))(c)(#)
Plan Category
Equity compensation plans approved by security holders(1)	5,431,268	$	1.36	1,322,222	(2)
Equity compensation plans not approved by security holders(3)	437,232	$	0.96	—
Total	5,868,500			1,322,222

________________________________

(1)Includes the 2021 Incentive Plan.

(2)Includes 1,322,222 shares reserved for issuance under the 2021 Incentive Plan as of December 31, 2025. The number of shares of common stock reserved for issuance under the 2021 Incentive Plan will automatically increase on January 1 of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our Board. Pursuant to the terms of the 2021 Incentive Plan, an additional 3,675,167 shares were added to the number of available shares effective January 1, 2026.

(3)Represents stock options issued as inducement awards outside the 2021 Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

DELINQUENT SECTION 16(a) REPORTS

Section 16(a) of the Exchange Act requires our officers and directors, and persons who beneficially own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the SEC.

Table of Contents

To our knowledge, based solely on a review of the Section 16(a) reports filed electronically with the SEC during the year ended December 31, 2025 and written representations that no other reports were required, all Section 16(a) filing requirements were timely met with respect to the year ended December 31, 2025.

Table of Contents

TRANSACTIONS WITH RELATED PERSONS

Since January 1, 2024, there have been no transactions to which we have been a participant in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year end for the last two completed fiscal years, and in which any of our then directors, executive officers or holders of more than 5% of any class of our capital stock at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which are described in “Executive Compensation” and “Director Compensation Table.”

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other annual meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other annual meeting materials addressed to those stockholders. This process, which is commonly referred to as "householding", potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are our stockholders will be "householding" our proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be "householding" communications to your address, "householding" will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in "householding" and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or Context Therapeutics Inc. Direct your request to Context Therapeutics Inc., Attn: Corporate Secretary, 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103 or by telephone at (267) 225-7416. The Company will deliver promptly, upon written or oral request, a separate Notice of Internet Availability of Proxy Material or other annual meeting materials to any stockholder at the shared address to which a single copy of the Notice of Internet Availability of Proxy Materials was delivered. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request "householding" of their communications should contact their brokers.

Table of Contents

OTHER MATTERS

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.


By Order of the Board of Directors,
/s/ ALEX LEVIT
Alex Levit Corporate Secretary April 28, 2026

A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission, is available without charge upon written request to: Context Therapeutics Inc., 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103

Table of Contents

APPENDIX A

PROPOSED AMENDMENT

TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

CONTEXT THERAPEUTICS INC.

The proposed amendment would provide that Article IV, Section 1 of the Amended and Restated Certificate of Incorporation be amended to read in its entirety as follows:

ARTICLE IV

Section 1. The Company is authorized to issue two classes of stock, to be designated, respectively, Common Stock and Undesignated Preferred Stock. The total number of shares of stock that the Company shall have authority to issue is 310,000,000 shares, of which 300,000,000 shares are Common Stock, $0.001 par value per share, and 10,000,000 shares are Undesignated Preferred Stock, $0.001 par value per share.

Table of Contents

PRELIMINARY COPY DATED APRIL 17, 2026, SUBJECT TO COMPLETION

CONTEXT THERAPEUTICS INC._V_PRXY_P46022_26(#96669) - C2_Page_1.jpg

Table of Contents

CONTEXT THERAPEUTICS INC._V_PRXY_P46022_26(#96669) - C2_Page_2.jpg

SEC Form PRE 14A filed by Context Therapeutics Inc.